Mycophenolate mofetil in low-risk renal transplantation in patients receiving no cyclosporine: a single-centre experience.

Hdl Handle:
http://hdl.handle.net/10147/136344
Title:
Mycophenolate mofetil in low-risk renal transplantation in patients receiving no cyclosporine: a single-centre experience.
Authors:
Raheem, Omer A; Daly, Padraig J; O'Kelly, Patrick; Shields, William P; Zimmerman, Antonio J; Mohan, Ponnusamy; Power, Richard; Little, Dilly M; Conlon, Peter J; Hickey, David P
Affiliation:
1Department of Urology and Transplantation, Beaumont Hospital, Dublin, Ireland.
Citation:
Mycophenolate mofetil in low-risk renal transplantation in patients receiving no cyclosporine: a single-centre experience. 2011:notNephrol Dial Transplant
Journal:
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Issue Date:
28-May-2011
URI:
http://hdl.handle.net/10147/136344
DOI:
10.1093/ndt/gfr263
PubMed ID:
21622991
Additional Links:
http://www.ncbi.nlm.nih.gov/pubmed/21622991
Abstract:
BACKGROUND: We assess our long-term experience with regards the safety and efficacy of Mycophenolate Mofetil (MMF) in our low risk renal transplant population and compared it retrospectively to Azathioprine (AZA) immunosuppressive regimen. Patients and methods. Between January 1999 and December 2005, 240 renal transplants received MMF as part of their immunosuppressive protocol (MMF group). AZA group of 135 renal transplants was included for comparative analysis (AZA group). Patients received Cyclosporine was excluded from this study. RESULTS: The incidence of biopsy proven 3-month acute rejections was 30 (12.5%) in MMF group and 22 (16%) in AZA group respectively (P = 0.307). Patient survival rates at 1 and 5 years for the MMF group were 97 and 94%, respectively, compared to 100% and 91% at 1 and 5 years respectively for the AZA group (P = 0.61). Graft survival rates at 1 and 5 years for the MMF group were 95 and 83%, respectively, compared to 97 and 84% at 1 and 5 years, respectively for the AZA group (P = 0.62). CONCLUSION: There was no difference in acute rejection episodes between MMF and AZA based immunotherapy. Additionally, we observed no significant difference concerning graft survival in the MMF group when compared to AZA group.
Item Type:
Article
Language:
en
ISSN:
1460-2385

Full metadata record

DC FieldValue Language
dc.contributor.authorRaheem, Omer Aen
dc.contributor.authorDaly, Padraig Jen
dc.contributor.authorO'Kelly, Patricken
dc.contributor.authorShields, William Pen
dc.contributor.authorZimmerman, Antonio Jen
dc.contributor.authorMohan, Ponnusamyen
dc.contributor.authorPower, Richarden
dc.contributor.authorLittle, Dilly Men
dc.contributor.authorConlon, Peter Jen
dc.contributor.authorHickey, David Pen
dc.date.accessioned2011-07-19T14:14:26Z-
dc.date.available2011-07-19T14:14:26Z-
dc.date.issued2011-05-28-
dc.identifier.citationMycophenolate mofetil in low-risk renal transplantation in patients receiving no cyclosporine: a single-centre experience. 2011:notNephrol Dial Transplanten
dc.identifier.issn1460-2385-
dc.identifier.pmid21622991-
dc.identifier.doi10.1093/ndt/gfr263-
dc.identifier.urihttp://hdl.handle.net/10147/136344-
dc.description.abstractBACKGROUND: We assess our long-term experience with regards the safety and efficacy of Mycophenolate Mofetil (MMF) in our low risk renal transplant population and compared it retrospectively to Azathioprine (AZA) immunosuppressive regimen. Patients and methods. Between January 1999 and December 2005, 240 renal transplants received MMF as part of their immunosuppressive protocol (MMF group). AZA group of 135 renal transplants was included for comparative analysis (AZA group). Patients received Cyclosporine was excluded from this study. RESULTS: The incidence of biopsy proven 3-month acute rejections was 30 (12.5%) in MMF group and 22 (16%) in AZA group respectively (P = 0.307). Patient survival rates at 1 and 5 years for the MMF group were 97 and 94%, respectively, compared to 100% and 91% at 1 and 5 years respectively for the AZA group (P = 0.61). Graft survival rates at 1 and 5 years for the MMF group were 95 and 83%, respectively, compared to 97 and 84% at 1 and 5 years, respectively for the AZA group (P = 0.62). CONCLUSION: There was no difference in acute rejection episodes between MMF and AZA based immunotherapy. Additionally, we observed no significant difference concerning graft survival in the MMF group when compared to AZA group.-
dc.languageENG-
dc.language.isoenen
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/21622991en
dc.titleMycophenolate mofetil in low-risk renal transplantation in patients receiving no cyclosporine: a single-centre experience.en
dc.typeArticleen
dc.contributor.department1Department of Urology and Transplantation, Beaumont Hospital, Dublin, Ireland.en
dc.identifier.journalNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Associationen
dc.description.provinceLeinster-
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.